BR0316261A - Composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade caracterizada por renovação, ativação, ou renovação e ativação de leucócitos patogênicos e método de antagonização de um receptor de quimioquinas c-c 1 em um paciente - Google Patents

Composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade caracterizada por renovação, ativação, ou renovação e ativação de leucócitos patogênicos e método de antagonização de um receptor de quimioquinas c-c 1 em um paciente

Info

Publication number
BR0316261A
BR0316261A BR0316261A BR0316261A BR0316261A BR 0316261 A BR0316261 A BR 0316261A BR 0316261 A BR0316261 A BR 0316261A BR 0316261 A BR0316261 A BR 0316261A BR 0316261 A BR0316261 A BR 0316261A
Authority
BR
Brazil
Prior art keywords
renewal
activation
treating
patient
compound
Prior art date
Application number
BR0316261A
Other languages
English (en)
Inventor
Kenneth G Carson
Geraldine C B Harriman
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BR0316261A publication Critical patent/BR0316261A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA QUE COMPREENDE O MESMO, MéTODO PARA TRATAR UMA ENFERMIDADE CARACTERIZADA POR RENOVAçãO, ATIVAçãO, OU RENOVAçãO E ATIAVçãO DE LEUCóCITOS PATOGêNICOS E MéTODO DE ANTAGONIZAçãO DE UM RECEPTOR DE QUIMIOQUINAS C-C 1 EM UM PACIENTE A invenção proporciona compostos que são dotados da fórmula (I): em que R¬ 1¬ é halogênio. A invenção também proporciona composições que compreendem os compostos, e métodos de tratamento de enfermidades ou distúrbios os quais compreendem administrar um ou mais dos compostos a um paciente com necessidade do mesmo. Os compostos expostos são dotados de atividade antagonista CCR1.
BR0316261A 2002-11-13 2003-11-12 Composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade caracterizada por renovação, ativação, ou renovação e ativação de leucócitos patogênicos e método de antagonização de um receptor de quimioquinas c-c 1 em um paciente BR0316261A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42594702P 2002-11-13 2002-11-13
PCT/US2003/035817 WO2004043965A1 (en) 2002-11-13 2003-11-12 Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease

Publications (1)

Publication Number Publication Date
BR0316261A true BR0316261A (pt) 2005-10-11

Family

ID=32313083

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316261A BR0316261A (pt) 2002-11-13 2003-11-12 Composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade caracterizada por renovação, ativação, ou renovação e ativação de leucócitos patogênicos e método de antagonização de um receptor de quimioquinas c-c 1 em um paciente

Country Status (25)

Country Link
US (7) US20040106639A1 (pt)
EP (2) EP1669356B1 (pt)
JP (1) JP4644491B2 (pt)
KR (1) KR101109348B1 (pt)
CN (1) CN100343257C (pt)
AR (1) AR041942A1 (pt)
AT (2) ATE468340T1 (pt)
AU (2) AU2003291452A1 (pt)
BR (1) BR0316261A (pt)
CA (1) CA2505874C (pt)
CY (1) CY1107985T1 (pt)
DE (2) DE60305063T2 (pt)
DK (1) DK1562954T3 (pt)
EA (1) EA007748B1 (pt)
ES (2) ES2261979T3 (pt)
HK (2) HK1074046A1 (pt)
IL (2) IL168384A (pt)
MX (1) MXPA05005105A (pt)
NO (1) NO331855B1 (pt)
PL (1) PL211022B1 (pt)
PT (1) PT1562954E (pt)
SI (1) SI1562954T1 (pt)
TW (1) TWI291467B (pt)
WO (1) WO2004043965A1 (pt)
ZA (2) ZA200504144B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
US7960549B2 (en) * 2004-12-17 2011-06-14 Carole Neves Solid forms of a chemokine receptor antagonist and methods of use thereof
BRPI0516383A (pt) 2004-12-21 2008-09-02 Serono Lab derivados cìclicos de sulfonil amino e o uso dos mesmos
EP1844032B1 (en) 2005-01-31 2011-07-13 Merck Serono SA N-hydroxyamide derivatives and use thereof
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
JP2009507003A (ja) 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
EA014695B1 (ru) 2006-07-14 2010-12-30 Эли Лилли Энд Компани Модулятор рецепторов глюкокортикостероидов и его применение
CN101808991A (zh) * 2007-07-24 2010-08-18 百时美施贵宝公司 作为趋化因子受体活性调节剂的哌啶基衍生物
WO2009082526A2 (en) * 2007-10-05 2009-07-02 Pharmacopeia, Inc. Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
JP2011505364A (ja) * 2007-11-30 2011-02-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ＴＭＥＤＡを用いた５−シクロプロピル−５，１１−ジヒドロ［１］ベンゾオキセピノ［３，４−ｂ］−ピリジン−５−オールの製造方法
US20090286823A1 (en) * 2007-12-17 2009-11-19 Millennium Pharmaceuticals Inc. CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders
AU2009204155A1 (en) 2008-01-11 2009-07-16 Eli Lilly And Company (E)-N-{3- [1-(8-Fluoro-11H-10-oxa-1-aza-dibenzo [a,d] cyclohepten-5ylidene)-propyl]-phenyl }-methynsulfon amide as glucocorticoid receptor modulator for the treatment of rheumatoid
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80449C (pt)
DD80449A (pt)
US377729A (en) * 1888-02-07 Half to phillips
GB1003292A (en) 1960-12-08 1965-09-02 Sandoz Ag Improvements in or relating to 4-azathiaxanthene derivatives
NL279409A (pt) 1961-06-08
CH416624A (de) 1962-10-23 1966-07-15 Sandoz Ag Verfahren zur Herstellung von neuen heterocyclischen Verbindungen
NL132137C (pt) * 1963-04-24
FR88751E (pt) 1963-07-09 1967-06-07
GB1085405A (en) 1963-10-14 1967-10-04 Pfizer & Co C Dibenzoxepins and dibenzthiepins
FR145F (pt) 1964-06-01
CH421138A (de) 1965-11-04 1966-09-30 Wander Ag Dr A Verfahren zur Herstellung von Thioxanthenderivaten
US3409621A (en) * 1966-04-01 1968-11-05 Schering Corp Piperazino-aza-dibenzo-[a, d]-cycloheptenes
US3625974A (en) 1967-04-28 1971-12-07 Fujisawa Pharmaceutical Co Dibenzothiazepine derivatives
GB1206216A (en) 1967-07-18 1970-09-23 Pfizer & Co C Aminopropylidene dibenzoxepine tranquilizers
NL6905642A (pt) 1968-04-12 1969-10-14
JPS4830064B1 (pt) 1968-12-23 1973-09-17
JPS4840356Y1 (pt) 1969-12-22 1973-11-27
US3770729A (en) * 1970-12-22 1973-11-06 Yoshitomi Pharmaceutical N substituted piperidine compounds
GB1330966A (en) 1970-12-22 1973-09-19 Yoshitomi Pharmaceutical N-substituted piperidine compounds methods for their production and pharmaceutical compositions containing them
JPS5146625Y2 (pt) 1971-03-24 1976-11-10
GB1323659A (en) 1971-04-10 1973-07-18 Yoshitomi Pharmaceutical Piperazine derivatives methods for their production and pharmaceuticl compositions containing them
CA1010870A (en) * 1972-12-08 1977-05-24 Niels Lassen Thiaxanthene derivative and method
US4250176A (en) * 1976-12-21 1981-02-10 Janssen Pharmaceutica N.V. Piperazine derivatives
US4335122A (en) * 1981-03-18 1982-06-15 Hoechst-Roussel Pharmaceuticals Inc. Dihydro-dibenzoxepines-thiepines and -morphanthridones, compositions and use
DE3326641A1 (de) 1982-07-27 1984-02-02 Basf Ag, 6700 Ludwigshafen 5,6-dihydro-11-h-morphantridin-6-one, ihre herstellung und diese enthaltende arzneimittel
US4547496A (en) * 1983-06-24 1985-10-15 Kyowa Hakko Kogyo Co., Ltd. Antiulcer [1] benzepino[3,4-b]pyridine and compositions
ES8502099A1 (es) 1983-08-02 1984-12-16 Espanola Farma Therapeut Procedimiento de obtencion de nuevos compuestos derivados de la difenil-metilen-etilamina.
DE3402060A1 (de) * 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CS236550B1 (cs) 1984-02-02 1985-05-15 Miroslav Protiva Způsob přípravy esterů piperazinoalkanolů dibenzo(b,e)thiepinové řady a jejich solí s kyselinou maleinovou
CS236549B1 (cs) 1984-02-02 1985-05-15 Miroslav Protiva Piperazinoalkanoly dibenzo(b,e)thiepinové řady a jejich soli s kyselinou maleinovou
CS240698B1 (cs) 1984-10-12 1986-02-13 Miroslav Protiva Substituované ll-(piperidinoalkyl)-6,ll-dihydrodibenzo (b,e)thiepin-ll-karbonitrily
JPH0665664B2 (ja) 1985-01-18 1994-08-24 大塚製薬株式会社 モルフアントリジン誘導体
SE8500273D0 (sv) * 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
WO1988000049A1 (en) 1986-06-26 1988-01-14 Kyowa Hakko Kogyo Co., Ltd. Antiarrhythmic agent
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
IT8721978A0 (it) 1987-09-21 1987-09-21 Angeli Inst Spa Nuovi derivati ammidinici triciclici.
US4882351A (en) * 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
ES2056214T3 (es) 1988-04-28 1994-10-01 Schering Corp Compuestos de benzopirido-piperidina, -piperidilideno y -piperazina, composiciones, metodos de preparacion y metodos de uso.
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
DE3838912A1 (de) * 1988-11-17 1990-05-23 Thomae Gmbh Dr K Mittel zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen
JPH0694464B2 (ja) * 1991-01-23 1994-11-24 協和醗酵工業株式会社 三環式化合物およびその中間体
US5239083A (en) * 1991-03-11 1993-08-24 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives which inhibit steroid 5α reductase
WO1992016226A1 (en) 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
CA2109702A1 (en) 1991-05-23 1992-11-26 Jesse K. Wong Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
EP0524784A1 (en) 1991-07-23 1993-01-27 Schering Corporation Benzopyrido piperidylidene compounds as PAF antagonists
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US5679703A (en) * 1992-09-16 1997-10-21 Kyowa Hakko Kogyo, Co., Ltd. Tricyclic compounds having ACAT inhibiting activity
EP0669979B1 (en) 1992-11-10 2005-10-12 Genentech, Inc. C-c ckr-1, c-c chemokine receptor
US5538986A (en) * 1993-12-06 1996-07-23 Schering Corporation Tricyclic derivatives, compositions and methods of use
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
UA54385C2 (uk) * 1995-04-07 2003-03-17 Ново Нордіск А/С N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU5271096A (en) 1995-04-07 1996-10-23 Novo Nordisk A/S Novel heterocyclic compounds
WO1996031469A1 (en) 1995-04-07 1996-10-10 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
JPH0940662A (ja) 1995-05-24 1997-02-10 Kyowa Hakko Kogyo Co Ltd 三環式化合物
US6150355A (en) * 1995-09-13 2000-11-21 Kyowa Hakko Kogyo Co., Ltd. Phenylpiperidine derivative
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
DE29602088U1 (de) 1996-02-07 1996-04-04 Buemach Engineering Internatio Verschraubbarer druckmittelbetätigter Arbeitszylinder mit Verschlußteilen zur Kopplung des Zylinderrohres
EP0914319B1 (en) 1996-05-20 2001-11-21 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
US6323206B1 (en) 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト，インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
WO1998004554A1 (fr) 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Antagonistes de recepteurs de chemokines
CA2266015C (en) 1996-09-13 2003-12-30 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
SK33599A3 (en) 1996-09-13 2000-03-13 Schering Corp Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
WO1998011106A1 (en) 1996-09-13 1998-03-19 Schering Corporation Tricyclic compounds useful as fpt inhibitors
WO1998011097A1 (en) 1996-09-13 1998-03-19 Schering Corporation Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase
KR20000036059A (ko) 1996-09-13 2000-06-26 둘락 노먼 씨. Ｇ-단백질 기능의 억제 및 증식성 질환의 치료에 유용한트리사이클릭 화합물
KR20000036120A (ko) 1996-09-13 2000-06-26 둘락 노먼 씨. 파르네실 단백질 트랜스퍼라제에 대한 트리사이클릭 저해제
WO1998011098A1 (en) 1996-09-13 1998-03-19 Schering Corporation Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
CZ114199A3 (cs) 1996-10-04 1999-09-15 Novo Nordisk A/S N-Substituované azaheterocyklické sloučeniny
KR20000048899A (ko) 1996-10-04 2000-07-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 1,4-디치환 피페라진
ZA978792B (en) 1996-10-04 1998-04-06 Novo Nordisk As N-substituted azaheterocyclic compounds.
AU5803398A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025604A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AU5812498A (en) 1996-12-20 1998-07-17 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AU6517398A (en) 1997-03-27 1998-10-22 Kyowa Hakko Kogyo Co. Ltd. Therapeutic agent for autoimmune diseases
US5877177A (en) * 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6040318A (en) 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids
JP2002515914A (ja) 1997-06-25 2002-05-28 ノボ ノルディスク アクティーゼルスカブ 新規へテロ環式化合物
US6048856A (en) * 1997-12-17 2000-04-11 Novo Nordisk A/S Heterocyclic compounds
EP1047675A1 (en) * 1998-01-21 2000-11-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
ID26618A (id) * 1998-01-21 2001-01-25 Millennium Pharm Inc Antagonis-antagonis reseptor kemokin dan metode penggunaannya
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
HU228314B1 (hu) 1998-09-04 2013-03-28 Millennium Pharmaceuticals Kemokin receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
US6503926B2 (en) 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2343536A1 (en) 1998-09-04 2000-03-16 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
EP1135129A1 (en) 1998-12-02 2001-09-26 Novo Nordisk A/S Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
WO2001009137A1 (en) * 1999-07-28 2001-02-08 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU6499100A (en) 1999-07-28 2001-02-19 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
NZ532827A (en) * 2001-11-21 2007-09-28 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
WO2006114870A1 (ja) 2005-04-20 2006-11-02 Mitsubishi Denki Kabushiki Kaisha 過電流継電器
JP4715952B2 (ja) 2009-02-18 2011-07-06 村田機械株式会社 フロッグレッグ型移載装置

Also Published As

Publication number Publication date
WO2004043965A1 (en) 2004-05-27
EA007748B1 (ru) 2006-12-29
IL210046A0 (en) 2011-07-31
EP1669356B1 (en) 2010-05-19
CA2505874C (en) 2012-07-17
IL210046A (en) 2015-07-30
AU2003291452A1 (en) 2004-06-03
EP1669356A1 (en) 2006-06-14
DE60305063D1 (de) 2006-06-08
DE60305063T2 (de) 2006-11-16
DE60332663D1 (de) 2010-07-01
US20100249174A1 (en) 2010-09-30
US20050288319A1 (en) 2005-12-29
US20040106639A1 (en) 2004-06-03
TWI291467B (en) 2007-12-21
AR041942A1 (es) 2005-06-01
US20150005338A1 (en) 2015-01-01
US8394817B2 (en) 2013-03-12
US20110230516A1 (en) 2011-09-22
JP2006508966A (ja) 2006-03-16
PT1562954E (pt) 2006-07-31
AU2008202965A1 (en) 2008-07-31
CN1738824A (zh) 2006-02-22
EP1562954B1 (en) 2006-05-03
ATE325124T1 (de) 2006-06-15
MXPA05005105A (es) 2005-07-01
US20130289063A1 (en) 2013-10-31
AU2008202965B2 (en) 2012-03-22
PL377715A1 (pl) 2006-02-06
US7977350B2 (en) 2011-07-12
ZA200504144B (en) 2007-04-25
CN100343257C (zh) 2007-10-17
US9334283B2 (en) 2016-05-10
HK1074046A1 (en) 2005-10-28
US20080139602A1 (en) 2008-06-12
CY1107985T1 (el) 2013-09-04
CA2505874A1 (en) 2004-05-27
KR20050074609A (ko) 2005-07-18
ES2261979T3 (es) 2006-11-16
IL168384A (en) 2011-01-31
ZA200607868B (en) 2008-01-08
ES2346337T3 (es) 2010-10-14
PL211022B1 (pl) 2012-03-30
US7732459B2 (en) 2010-06-08
ATE468340T1 (de) 2010-06-15
TW200413347A (en) 2004-08-01
KR101109348B1 (ko) 2012-01-31
NO20052272L (no) 2005-06-06
HK1086011A1 (en) 2006-09-08
NO331855B1 (no) 2012-04-23
JP4644491B2 (ja) 2011-03-02
EP1562954A1 (en) 2005-08-17
DK1562954T3 (da) 2006-08-28
EA200500803A1 (ru) 2005-10-27
SI1562954T1 (sl) 2006-10-31

Similar Documents

Publication Publication Date Title
BR0316261A (pt) Composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade caracterizada por renovação, ativação, ou renovação e ativação de leucócitos patogênicos e método de antagonização de um receptor de quimioquinas c-c 1 em um paciente
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
BR0012450A (pt) Benzimidazóis substituìdos
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BRPI0509576A (pt) composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
CY1112932T1 (el) Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
WO2003004480A3 (en) Substituted piperazine and diazepanes as histamine h3 receptor agonists
BRPI0408005A (pt) composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor
BRPI0417260A (pt) derivados de azepinoindol como agentes farmacêuticos
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR0317430A (pt) Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
BR9811093A (pt) Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
BR0215801A (pt) Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
SE9903894D0 (sv) Novel compounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL